French Electrical Stock News

JCDecaux stock came into today sitting near a strong run, up about 20% over the past three months and closing at €22.64 on 31 July. The market liked the direction of travel in the short term. The real story in these half year numbers sits deeper than the price chart. H1 2026 landed with a clear headline. Profitability tightened meaningfully, with operating margin up to 18.4% and recurring EBIT margin at 7.0%, while free cash flow swung into positive territory at €26.2m. For long term...

Thales (ENXTPA:HO) has been in focus after the Civil Aviation Authority of Singapore selected the company to develop the country’s NexGen Air Traffic Management System and air traffic control radars, replacing the existing LORADS III system. See our latest analysis for Thales. Set against a series of recent defence and aviation contract announcements, Thales’ share price has a 1 month share price return of 8.23% and a 5 year total shareholder return above 200%, which points to solid longer...

In late July 2026, Ipsos SA’s Board appointed long-time executive Kelly Beaver as Chief Executive Officer, succeeding Jean Laurent Poitou following his launch of the Horizons plan earlier that year. Beaver’s blend of internal leadership roles, AI-oriented healthcare experience, and external recognition for research excellence positions her to influence how Ipsos pursues acquisitions and technology integration. We’ll now examine how Beaver’s appointment, given her track record in AI-enabled...

Dassault Systèmes (ENXTPA:DSY) is in focus after its Medidata unit launched Medidata Plus, an AI layer that integrates artificial intelligence across the Medidata clinical trial platform to support an end to end AI strategy. See our latest analysis for Dassault Systèmes. The Medidata Plus launch and recent talk of a possible ArisGlobal acquisition come as Dassault Systèmes trades at €20.21, with a 1 month share price return of 13.44% but a 1 year total shareholder return that has declined...

Air France-KLM (ENXTPA:AF) is back in focus after its H1 2026 results on 30 July, which combined higher group revenue and updated capacity guidance with pressure on profitability from sharply higher fuel costs. See our latest analysis for Air France-KLM. The Air France-KLM share price has reacted quickly to the H1 2026 update, with a 4.18% 1 day and 9.79% 7 day share price return. The 90 day share price return of 36.18% contrasts with a 5 year total shareholder return that is down 41.05%,...

The European market has recently shown resilience, with the STOXX Europe 600 Index ending the week up and major indices like Germany's DAX and France's CAC 40 posting gains. Amidst these developments, investors are increasingly exploring opportunities in less conventional areas such as penny stocks. Although the term "penny stock" may seem outdated, it still represents smaller or newer companies that can offer significant value when backed by strong financials. This article will explore three...

Bureau Veritas went into this earnings print with a solid recent run, the stock up about 7% over the past three months and closing at €27.91 just after the release. The market had been paying for the quality story, with a P/E of 24.6x sitting between higher priced peers and cheaper European professional services stocks. The headline from H1 2026 is tighter profitability. Net margin over the last twelve months sat at 7.5% compared with 9.9% a year earlier, even as revenue reached about €6.7b...

Half year earnings put Lagardere (ENXTPA:MMB) back in focus Lagardere (ENXTPA:MMB) is back on investors’ radar after reporting half year 2026 results, with sales of €4,436 million, revenue of €4,466 million, and net income of €31 million on continuing operations. See our latest analysis for Lagardere. Despite the half year earnings news, Lagardere’s share price has been relatively subdued, with a 7 day share price return of 2.72%, while the year to date share price return is down 3.10% and...

As you might know, Métropole Télévision S.A. ( EPA:MMT ) recently reported its interim numbers. Métropole Télévision...

Altarea’s share price has inched higher in recent weeks, yet the real story sits in the earnings power behind that move. The headline is simple: the stock now trades on a rich P/E of 66.3x while the balance sheet still carries clear stress. Funds From Operations, the key profitability lens for a property group, stands at €144.9 million over the last twelve months and the company has moved into profit. At the same time, the dividend yield of 7.86% is not well covered and debt coverage by...

The market has spent the past month pushing Nexans lower, with the stock down about 9% over 30 days and 17% over three months, yet today's earnings story centers on profit resilience rather than a collapse. The key tension is margin quality. Adjusted EBITDA for the first half stands at €388m on €4.736b of revenue, while trailing net profit margin sits at 2.3%. For a capital heavy grid and transmission player, that mix of solid operating profit and a thin bottom line invites a sentiment reset...

Hermès International came into these results with the stock drifting, down about 4.5% over three months, and trading on a rich P/E of 36x. The headline from H1 is not explosive growth. It is the sheer resilience of ultra high profitability. Revenue reached €8.2b with an operating margin of 41% and a trailing net margin around 28%. For a luxury house already at this scale, holding that level of profitability is the real story. This helps explain why the market is still willing to pay a premium...

Readers hoping to buy Wavestone SA ( EPA:WAVE ) for its dividend will need to make their move shortly, as the stock is...

L'Air Liquide S.A. ( EPA:AI ) shareholders are probably feeling a little disappointed, since its shares fell 2.2% to...

It looks like Quadient S.A. ( EPA:QDT ) is about to go ex-dividend in the next three days. The ex-dividend date is...

X-FAB Silicon Foundries (ENXTPA:XFAB) recently issued earnings guidance for the third quarter of 2026, telling investors it expects revenue between US$195 million and US$205 million, a range that can influence how you assess the stock. See our latest analysis for X-FAB Silicon Foundries. The latest guidance lands while X-FAB Silicon Foundries’ share price sits at €6.78, with a 1-day share price return of 7.11% but a 30-day share price return down 14.34%, and longer term total shareholder...

The market had already priced Airbus as a steady compounder, with the stock up 16.7% over the past three months and closing at €204 just as the Q2 numbers landed. The earnings story that arrived was about one thing above all else: profitability. Net income excluding extra items reached €1.66b on revenue of €20.53b, and basic earnings per share came in at €2.10. The gap between the calm share price and a profit engine that has been running harder sets up a clear question for investors: Who is...

Renault stock closed at €27.97 after the market had a full day to process the H1 2026 earnings. The short term story is simple. The share price is roughly flat over the past week while investors digest a set of numbers that show the group firmly back in profit over the last 12 months despite a very large one off loss earlier in the period. The focus for many investors is on a longer horizon. The stock currently trades on a low P/E ratio and its market value is well below some estimates of...

FDJ United stock closed at €22.4 after a choppy week that left short term holders nursing a small loss. The headline story is not the share price. It is the squeeze in profitability that runs through these results. Net profit over the last twelve months came in at €24m on €3.59b of revenue, which works out to a 0.7% margin compared with 9.2% a year earlier. That gap sits at the heart of today’s earnings debate. You are deciding whether this is a temporary hit or a reset in how FDJ United now...

Altareit’s share price has barely moved over the past week, yet the latest half year numbers confront investors with the same uncomfortable question. How much patience is left for a stock that still trades on a low 0.5x price to sales multiple while posting another loss in the tens of millions of euro. The headline this time is not revenue. It is the strain from continued losses and weak debt coverage sitting on a highly discounted valuation. Today’s flat reaction looks more like a pause...

Hermès International Société en commandite par actions has seen its share price fall 32.9% over the past year, yet the valuation checks still suggest the stock is not a clear bargain. Over the last 12 months the stock is down 32.9%, which means recent buyers have faced a sharp reset in expectations. Stronger sales in leather goods and solid profitability can support the current market price, but softer areas such as perfume and beauty and regional pressures may weigh on how much investors...

Global inflation, energy prices and geopolitics are keeping markets on edge, yet they also keep attention on sectors tied to long-term government spending such as aerospace and defense. With central banks juggling growth and inflation, and consumer confidence improving in some regions but not others, many investors are looking for companies whose demand is shaped more by policy priorities than by short term swings in sentiment. The Aerospace And Defense screener helps you filter this space...

EssilorLuxottica Société anonyme walked into this earnings season with a premium P/E and a reputation as a quality compounder. Yet the stock closed at about €165.1 on 29 July, and is down roughly 9% over the past 90 days. The gap between that softer share price and the latest numbers is now front and center. The headline is margin quality. H1 2026 delivered adjusted operating profit growth faster than revenue, a higher gross margin and the strongest first half free cash flow in five years at...

Why the amlitelimab decision matters for Sanofi shareholders Sanofi (ENXTPA:SAN) is halting development of amlitelimab for moderate to severe atopic dermatitis after a pipeline review concluded the efficacy and safety profile did not justify regulatory submissions compared with current treatments. The company cited long term phase 3 data showing maintained clinical response and an emerging safety profile, yet still judged amlitelimab would not offer a meaningful improvement over existing...